CRIS Current Research Information System

GUADAGNUOLO, VIVIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.823
EU - Europa 4.518
AS - Asia 4.233
AF - Africa 407
SA - Sud America 246
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 9
Totale 15.246
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.754
GB - Regno Unito 1.257
SG - Singapore 1.222
CN - Cina 1.169
VN - Vietnam 999
SE - Svezia 701
DE - Germania 626
IT - Italia 576
HK - Hong Kong 332
IN - India 246
RU - Federazione Russa 214
FR - Francia 212
NL - Olanda 178
IE - Irlanda 177
BR - Brasile 170
TG - Togo 110
ZA - Sudafrica 101
NG - Nigeria 95
EE - Estonia 92
UA - Ucraina 89
CH - Svizzera 85
FI - Finlandia 80
CI - Costa d'Avorio 70
BG - Bulgaria 59
CA - Canada 52
BE - Belgio 50
JO - Giordania 46
AR - Argentina 43
GR - Grecia 39
KR - Corea 39
JP - Giappone 33
IR - Iran 30
ID - Indonesia 23
BD - Bangladesh 19
PL - Polonia 19
SC - Seychelles 18
AT - Austria 17
ES - Italia 15
MX - Messico 13
TR - Turchia 10
IQ - Iraq 9
UZ - Uzbekistan 9
CL - Cile 8
EC - Ecuador 8
AU - Australia 7
EU - Europa 7
LB - Libano 7
PE - Perù 6
PK - Pakistan 6
LT - Lituania 5
MA - Marocco 5
MK - Macedonia 5
PH - Filippine 5
AE - Emirati Arabi Uniti 4
CZ - Repubblica Ceca 4
PY - Paraguay 4
RO - Romania 4
A2 - ???statistics.table.value.countryCode.A2??? 3
HR - Croazia 3
IL - Israele 3
KZ - Kazakistan 3
MY - Malesia 3
PT - Portogallo 3
AZ - Azerbaigian 2
CO - Colombia 2
GY - Guiana 2
KE - Kenya 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
SA - Arabia Saudita 2
TM - Turkmenistan 2
TN - Tunisia 2
VE - Venezuela 2
BH - Bahrain 1
CY - Cipro 1
DM - Dominica 1
DZ - Algeria 1
EG - Egitto 1
GE - Georgia 1
HN - Honduras 1
HU - Ungheria 1
KG - Kirghizistan 1
KH - Cambogia 1
MR - Mauritania 1
NI - Nicaragua 1
NP - Nepal 1
PS - Palestinian Territory 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UY - Uruguay 1
Totale 15.246
Salva come PNG Salva come JPEG
Città #
Southend 1.164
Singapore 794
Dong Ket 660
Ashburn 651
Chandler 605
Fairfield 539
Ann Arbor 374
Hong Kong 331
Houston 318
Beijing 290
Wilmington 269
Woodbridge 265
Seattle 264
Cambridge 204
Princeton 200
Santa Clara 196
Dublin 176
Boardman 143
Bologna 125
Lomé 110
Westminster 101
Nanjing 95
Padova 94
Hefei 86
Medford 86
New York 85
Bern 75
Los Angeles 74
Abidjan 70
Ho Chi Minh City 65
Helsinki 63
Abeokuta 61
Sofia 59
Munich 53
Brussels 50
Berlin 48
Bremen 46
Amman 45
Saint Petersburg 45
Shenyang 45
Nanchang 39
Redondo Beach 36
Redwood City 36
Hanoi 35
Redmond 35
Falls Church 34
Dallas 33
Hebei 33
San Diego 33
Buffalo 32
Florence 32
Frankfurt am Main 32
Jinan 32
Seoul 32
Toronto 30
Changsha 29
São Paulo 29
Turin 27
Tokyo 26
Jiaxing 24
Zhengzhou 23
Milan 22
Falkenstein 21
Shanghai 21
Mountain View 20
Tianjin 20
Norwalk 19
Guangzhou 17
Hangzhou 17
Turku 17
Jakarta 16
London 15
Hyderabad 14
Rome 14
Haikou 13
Jacksonville 13
Paris 13
Brooklyn 12
Ningbo 12
Chennai 11
Düsseldorf 11
Orem 11
Phoenix 11
Vienna 11
Bühl 10
Chengdu 10
Romainville 10
Roubaix 10
San Francisco 10
Fuzhou 9
Kunming 9
Nuremberg 9
Warsaw 9
Athens 8
Da Nang 8
Grafing 8
Montreal 8
Olalla 8
Stockholm 8
Taizhou 8
Totale 10.179
Salva come PNG Salva come JPEG
Nome #
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 336
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 315
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 271
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 260
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 242
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 240
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 232
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 218
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 215
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 213
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 211
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 210
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 206
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 202
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 202
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 201
A case report of acute myeloid leukemia and neurofibromatosis 1 198
Novel and rare fusion transcripts involving transcription factors and tumor suppressor genes in acute myeloid leukemia 198
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 196
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 185
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 182
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 180
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 174
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 173
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 173
Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 172
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 171
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 169
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients 169
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 164
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 164
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 162
Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients 162
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 160
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 159
Clec12a: A new AML stem cell-associated antigen 158
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 158
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 157
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 157
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 156
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 155
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 154
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 154
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 153
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 152
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 152
Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT) 151
You have accessEx-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 151
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 150
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 149
The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia 148
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 146
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 146
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 145
The PAX5gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemiabut is not associated with outcome. A report on behalf of the GIMEMA AcuteLeukemia Working Party 144
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 144
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 142
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 138
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis 136
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 135
Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia 133
SNP array reveals a new deletion of JAK2 in AML patients 133
The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia 130
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 130
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia 129
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 128
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 127
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 127
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 127
Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience 125
null 123
PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients 123
Novel fusion transcripts identified by RNAseq cooperate with somatic mutations in the pathogenesis of acute myeloid leukemia 122
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 121
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 121
Nelarabine front-line therapy for adult T-Lymphoblastic leukaemia/Lymphoma (T-LBL/ALL): preliminary results of a single centre experience 120
The role of the loss of CDKN2A gene on prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia (ALL) 119
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications 119
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 118
High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL) 118
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience 117
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience 117
PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients 115
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: follow up of a single-center Italian compassionate use 114
Ultra-Deep Sequencing Strategy Is a Precious Tool to Find Small Clones Harbouring FLT3 Mutations in AML Patients 114
Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience 113
Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL). 112
Gene expression signature of aneuploidy in acute myeloid leukemia 112
Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study 111
Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene 109
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 108
Next-Generation Sequencing Analysis Revealed That BCL11B Chromosomal Translocation Cooperates with Point Mutations in the Pathogenesis of Acute Myeloid Leukemia 107
New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients 107
NELARABINE FRONT-LINE THERAPY FOR ADULT T-LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA (T-LBL/ALL): PRELIMINARY RESULTS OF BOLOGNA EXPERIENCE 104
Molecular Characterization of PAX5 alterations in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) 104
SET-UP OF A MULTIPLEX PCR TO RAPIDLY DETECT IKZF1 (IKAROS) GENE BREAKPOINT DELETION IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 104
Nelarabine front-line therapy for adult T-lymphoblastic leukemia/lymphoma (T-LBL/ALL): preliminary results of a single center experience. 97
null 86
Loss of the tumor suppressor genes CDKN2A/ARF impairs prognosis in adult BCR-ABL1 positive acute lymphoblastic leukemia (ALL) 83
null 77
Totale 15.420
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.991
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.991
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.452 0 0 0 0 0 87 39 117 151 86 83 889
2021/20222.175 188 54 115 185 252 142 58 117 130 155 399 380
2022/20232.493 318 392 106 356 180 196 78 117 392 55 181 122
2023/2024653 28 102 23 61 35 171 52 43 50 28 26 34
2024/20252.244 91 360 183 163 286 76 203 78 19 250 84 451
2025/20262.286 440 303 381 300 624 238 0 0 0 0 0 0
Totale 15.560